Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Eric Marvin

Neurological Surgery Roanoke, VA Doctor of Osteopathy

NPI 1407016082 CMS profile 108260

1030 S Jefferson St, Roanoke, VA 24016

Open in the dashboard

General payments

$11,976

35 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$15,928 paid to institutions, not to them · program year 2019

Through program year 2025, Eric Marvin of Roanoke, VA is reported in the CMS Open Payments database as having received $11,976 across 35 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $15,928 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 72nd percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $174 4
2024 General $314 3
2023 General $901 10
2022 General $1,992 7
2021 General $114 4
2020 General $8,142 2
2019 General $339 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eric Marvin
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Eric Marvin were reported at $174. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Eric Marvin Neurological Surgery median Middle half National median
2019 $339 $582 $138–$3,006 $163
2020 $8,142 $294 $76–$2,174 $114
2021 $114 $387 $105–$2,432 $132
2022 $1,992 $542 $139–$2,989 $149
2023 $901 $534 $145–$2,697 $160
2024 $314 $574 $155–$3,046 $164
2025 $174 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medical Device Business Services, Inc. $9,773 6 payments
  2. DePuy Synthes Sales Inc. $989 10 payments
  3. Medtronic, Inc. $338 4 payments
  4. Medtronic USA, Inc. $267 3 payments
  5. Integra LifeSciences Corporation $203 6 payments
  6. Stryker Corporation $164 1 payment
  7. GT Medical Technologies, Inc $95 1 payment
  8. Nevro Corp. $50 1 payment
  9. Boston Scientific Corporation $44 1 payment
  10. Biocomposites Inc $38 1 payment
  11. Other $16 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $8,050 1 payment
  2. Food and Beverage $2,232 30 payments
  3. Travel and Lodging $1,694 4 payments
Products named General payments · program years 2019–2025
  1. EXPEDIUM $8,050 1 payment
  2. SKYLINE $8,050 1 payment
  3. SYNAPSE $8,050 1 payment
  4. CONDUIT $2,155 9 payments
  5. TRUMATCH $308 3 payments
  6. INTELLIS ADAPTIVESTIM $300 2 payments
  7. SYNTHECEL $277 3 payments
  8. ADHERUS AUTOSPRAY DURAL SEALANT $164 1 payment
  9. CODMAN CERTAS $131 4 payments
  10. CUSA CLARITY $131 4 payments
  11. Other $1,572 34 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

17

Median for Neurosurgery: 83

Drug cost

$233

Median for Neurosurgery: $872

Branded share of claims

0%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 17 $233

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 85 billing codes

Paid by Medicare

$277,973

Medicare's payments for the services billed

Medicare patients

583

Average age 74

Services billed

1,302

297 women, 286 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 70%
Diabetes 42%
Depression 35%
Ischemic heart disease 32%
Chronic kidney disease 32%
Heart failure 25%
Atrial fibrillation 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

35 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurological Surgery in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record